Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · CEO & President | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,278 |
Ending reported balance
After 2026-02-27 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-02-27 · Sale · Disposed 400 · Balance 137,878 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76). Row 2 · 2026-02-27 · Sale · Disposed 120 · Balance 137,758 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51). Row 3 · 2026-02-27 · Sale · Disposed 240 · Balance 137,518 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85). Row 4 · 2026-02-27 · Sale · Disposed 2,510 · Balance 135,008 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55). Row 5 · 2026-02-27 · Sale · Disposed 3,278 · Balance 131,730 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56). Row 6 · 2026-02-27 · Sale · Disposed 460 · Balance 131,270 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79). Row 7 · 2026-02-27 · Sale · Disposed 2,725 · Balance 128,545 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01). Row 8 · 2026-02-27 · Sale · Disposed 949 · Balance 127,596 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85). Row 9 · 2026-02-27 · Sale · Disposed 2,520 · Balance 125,076 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77). Row 10 · 2026-02-27 · Sale · Disposed 3,498 · Balance 121,578 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75). Row 11 · 2026-02-27 · Sale · Disposed 15,580 · Balance 105,998 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78). Row 12 · 2026-02-27 · Sale · Disposed 5,995 · Balance 100,003 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F14: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74). Row 13 · 2026-02-27 · Sale · Disposed 1,725 · Balance 98,278 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F15: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.
F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).
F4: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).
F5: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).
F6: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55).
F7: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).
F8: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).
F9: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).
F10: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).
F11: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).
F12: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).
F13: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).
F14: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).
F15: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ginkgo Bioworks Holdings, Inc.
Report date June 12, 2024 · Filed June 14, 2024
Section 16 reporting ended · disclosed 2024-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 186,002 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Exercise / conversion · Acquired 105,263 · Balance 186,002 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-12 · Exercise / conversion · Disposed 105,263 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 27 | $286.07 | $7,723.89 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 8 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,654 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $286.07 (range $285.72 to $286.63). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10 | $283.76 | $2,837.60 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,681 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4 | $282.74 | $1,130.96 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,691 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $282.74 (range $282.46 to $283.35). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6 | $281.74 | $1,690.44 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,695 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $281.74 (range $281.24 to $282.23). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9 | $280.47 | $2,524.23 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,701 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $280.47 (range $280.16 to $280.73). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7 | $279.70 | $1,957.90 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,710 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $279.70 (range $279.13 to $280.06). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6 | $276.40 | $1,658.40 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,717 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $276.40 (range $275.85 to $276.75). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2 | $274.37 | $548.74 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,723 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $274.37 (range $274.03 to $274.71). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 510 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · derivative · entry 9 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,567 Underlying: Common Stock · 510 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,564 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · derivative · entry 8 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,206 Underlying: Common Stock · 1,564 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 134 | $275.17 | $36,872.78 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,626 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $275.17 (range $274.60 to $275.30). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 864 | $274.04 | $236,770.56 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,760 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $274.04 (range $273.56 to $274.40). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 360 | $272.77 | $98,197.20 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,624 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $272.77 (range $272.44 to $273.30). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $271.92 | $81,576.00 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,984 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $271.92 (range $271.33 to $272.17). Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 416 | $270.35 | $112,465.60 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,284 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $270.35 (range $269.87 to $270.75). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 510 | $155.57 | $79,340.70 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,564 | $187.53 | $293,296.92 |
DisclosureSEC source: 0001209191-20-027885 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 111 | $239.13 | $26,543.43 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 9 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,626 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $239.13 (range $239.13 to $239.14). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 420 | $238.28 | $100,077.60 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 8 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,737 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.28 (range $238.01 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 320 | $236.71 | $75,747.20 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,157 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $236.71 (range $236.31 to $237.24). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 340 | $235.36 | $80,022.40 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,477 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.36 (range $235.13 to $235.56). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 660 | $234.41 | $154,710.60 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,817 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.41 (range $233.90 to $234.80). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 440 | $232.35 | $102,234.00 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,477 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.14 to $233.08). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 450 | $230.88 | $103,896.00 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,917 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.88 (range $230.48 to $231.38). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 893 | $229.72 | $205,139.96 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,367 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.17). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,898 | $239.23 | $693,288.54 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,260 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 129 | $245.75 | $31,701.75 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,158 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.36 to $245.86). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 260 | $244.94 | $63,684.40 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,287 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.94 (range $244.36 to $245.32). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 134 | $243.76 | $32,663.84 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,547 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.25 to $244.08). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 540 | $242.62 | $131,014.80 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,681 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.62 (range $242.25 to $243.21). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $241.71 | $29,005.20 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,221 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.71 (range $241.24 to $242.02). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 944 | $241.50 | $227,976.00 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,341 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 510 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · derivative · entry 10 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,077 Underlying: Common Stock · 510 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,564 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · derivative · entry 9 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,770 Underlying: Common Stock · 1,564 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 129 | $242.47 | $31,278.63 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 8 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,285 F3 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 271 | $240.75 | $65,243.25 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,414 F3 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F5 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $240.75 (range $240.40 to $241.12). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 423 | $239.69 | $101,388.87 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,685 F3 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F5 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $239.69 (range $239.20 to $240.19). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,251 | $238.76 | $298,688.76 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,108 F3 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F4 · price: Open market sales reported on this line occurred at a weighted average price of $238.76 (range $238.15 to $239.11). F5 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 510 | $155.57 | $79,340.70 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,564 | $187.53 | $293,296.92 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,285 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007485 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,898 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to buy) · Derivative | 4,692 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-058099 · doc4.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,334 Underlying: Common Stock · 4,692 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,692 | $219.37 | $1,029,284.04 |
DisclosureSEC source: 0001209191-19-058099 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,692 | $187.53 | $879,890.76 |
DisclosureSEC source: 0001209191-19-058099 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 61 | $205.95 | $12,562.95 |
DisclosureSEC source: 0001209191-19-057132 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 509 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-056327 · doc4.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,587 Underlying: Common Stock · 509 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 509 | $199.00 | $101,291.00 |
DisclosureSEC source: 0001209191-19-056327 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 509 | $155.57 | $79,185.13 |
DisclosureSEC source: 0001209191-19-056327 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,057 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-054635 · doc4.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 Underlying: Common Stock · 3,057 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.